ReposiTrak Adds 50 New Food and Beverage Suppliers to the Queue for the Rapidly Expanding Food Traceability Network
Retailers drive increased focus on food safety and traceability as 50 new suppliers enter the queue to join the ReposiTrak Traceability Network
SALT LAKE CITY, June 03, 2025--(BUSINESS WIRE)--ReposiTrak (NYSE:TRAK), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 50 food and beverage suppliers to the queue of companies joining the ReposiTrak Traceability Network® (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.
Among the 50 new suppliers are many whose customers require traceability for all foods, not only Food Traceability List foods. One is a company known for providing nuts, confections, and nostalgic snacks for more than 80 years. Another, founded more than 150 years ago, has deep roots in the snack food sector with their iconic cookies and crackers. A third began in the early 1970s and has grown into a global leader in specialty coffee, offering a wide range of premium beverages, packaged drinks and coffee products available in retail stores worldwide.
"Suppliers large and small can use ReposiTrak to share traceability data with their retail customers in the exact format those customers require," stated Randy Fields, chairman and CEO of ReposiTrak. "We run every traceability data file through a 500+ point error detection process, to ensure it meets both FDA regulations and the often-stricter requirements of retail partners, removing complexity and reducing the risk of noncompliance."
The ReposiTrak Traceability Network requires no additional hardware or software and the ReposiTrak team assists in making the connections needed under the new regulation. Suppliers can connect to an unlimited number of trading partners and share data for a low, flat fee.
About ReposiTrak
ReposiTrak (NYSE: TRAK) provides retailers, suppliers, food manufacturers and wholesalers with a robust solution suite to help reduce risk and remain in compliance with regulatory requirements, enhance operational controls and increase sales with unrivaled brand protection. Consisting of three product families – food traceability, compliance and risk management and supply chain solutions – ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit https://repositrak.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603078379/en/
Contacts
Investor Relations Contact:John Merrill, CFOInvestor-relations@repositrak.com
OrFNK IRRob Fink646.809.4048rob@fnkir.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
DEADLINE ALERT for LPRO and CIVI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, June 30, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected]. Open Lending Corporation (NASDAQ: LPRO ) Class Period: February 24, 2022 – March 31, 2025 Lead Plaintiff Deadline: June 30, 2025 The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants: (1) misrepresented the capabilities of the Company's risk-based pricing models; (2) issued materially misleading statements regarding the Company's profit share revenue; (3) failed to disclose the Company's 2021 and 2022 vintage loans had become worth significantly less than their corresponding outstanding loan balances; (4) misrepresented the underperformance of the Company's 2023 and 2024 vintage loans; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you are an Open Lending shareholder who suffered a loss, click here to participate. Civitas Resources, Inc. (NYSE: CIVI ) Class Period: February 27, 2024 – February 24, 2025 Lead Plaintiff Deadline: July 1, 2025 The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Civitas was highly likely to significantly reduce its oil production in 2025 as a result of, inter alia, declines following the production peak at the DJ Basin in the fourth quarter of 2024 and a low TIL count at the end of 2024; (2) increasing its oil production would require the Company to acquire additional acreage and development locations, thereby incurring significant debt and causing the Company to sell corporate assets to offset its acquisition costs; (3) the Company's financial condition would require it to implement disruptive cost reduction measures including a significant workforce reduction; (4) accordingly, Civitas's business and/or financial prospects, as well as its operational capabilities, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you are a Civitas shareholder who suffered a loss, click here to participate. Follow us for updates on Twitter: To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at If you inquire by email please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts The Law Offices of Frank R. Cruz, Los Angeles Frank R. Cruz, 310-914-5007 [email protected]
Associated Press
33 minutes ago
- Associated Press
Vitalgen's Gene Therapy Drug VGN-R09b for Primary Parkinson's Disease Receives FDA Fast Track Designation
SHANGHAI, CHINA, June 30, 2025 / / -- Shanghai Vitalgen BioPharma Co., Ltd. ('Vitalgen') announced that its gene therapy drug, VGN-R09b, for the treatment of Primary Parkinson's Disease (PD), has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). VGN-R09b received IND approvals in China and the US in 2024, as a first-in-class recombinant adeno-associated virus (rAAV) gene therapy that targets two key pathways for the treatment of Parkinson's Disease (PD). The Phase I/II clinical trials have been ongoing in China since September, 2024, with all six patients dosed in the Phase I dose-escalation study. Safety data shows that the product is well-tolerated with no findings of VGN-R09b-related adverse events. Preliminary efficacy readouts show that VGN-R09b has a rapid onset of action, with significant gait improvements within two weeks post-treatment. The MDS-UPDRS Part III OFF scores decreased significantly after one month, with an average of 25-point improvements (approximately 50% improvements from the baseline) at six months. Overall, the Hoehn-Yahr (H-Y) scores progressively decreased, along with a reduction in oral medication dosages. The FTD indicates FDA's recognition of the clinical potential of VGN-R09b, marking an important milestone for Vitalgen's expansion into the chronic disease area, and it also represents a global breakthrough for a Chinese gene therapy company in the neurodegenerative field. Together with its FDA IND approval in July 2024, this FTD further validates VGN-R09b's global development potential and will provide expedited support for its future US clinical trials and regulatory filings. About Fast Track Designation (FTD) FTD is an FDA program designed to accelerate the development and approval of drugs that treat serious or life-threatening conditions and have the potential to address unmet medical needs. According to the performance report from the FDA's Center for Biologics Evaluation and Research (CBER), over 800 products have applied for FTD, with a success rate of approximately 68%. After receiving FTD, applicants are given the opportunity for frequent discussions with the FDA regarding their drug development plans, thereby increasing development efficiency. If the product meets certain criteria, it can qualify for accelerated approval, priority review, and rolling reviews, which can further accelerate development and market approval processes. About Parkinson's Disease (PD) Parkinson's Disease (PD) is the second most common neurodegenerative disease, with fast-growing incidences. It is projected that the global PD patient numbers will increase to more than 25 million by 2050. Current PD treatments are primarily small-molecule drugs for symptom relief. As the disease progresses, patients gradually lose response to oral medication, and significant motor complications persist despite fine-tuning the treatment regimens. There is currently no available treatment to delay disease progression or improve long-term outcomes. a: Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modeling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952. doi:10.1136/bmj-2024-080952. About Vitalgen Vitalgen was founded in March 2020 as a cell and gene therapy (CGT) company based in Shanghai, China, dedicated to translating cutting-edge CGT technologies into clinically accessible treatments for patients worldwide. With proprietary intellectual property rights covering three core CGT platforms: ViVec® (AAV manufacturing platform), ViCas® (CRISPR gene-editing platform) and ViLNP® (Lipid nanoparticle delivery platform), Vitalgen has developed a diversified portfolio of innovative CGTs targeting CNS diseases, ophthalmic conditions, metabolic and hematologic disorders, and oncology, including multiple potential First-in-Class (FIC) products. Up-to-date, Vitalgen has received multiple rounds of investment from renowned venture funds and has established CGT R&D labs and operational centers in the Zhangjiang High-tech Park and a GMP commercial production facility in the Waigaoqiao Free Trade Zone, Shanghai, China. David Wu Vitalgen BioPharma email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
33 minutes ago
- Associated Press
Law Offices of Frank R. Cruz Encourages Reddit, Inc. (RDDT) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Jun 30, 2025-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Reddit, Inc. ('Reddit' or the 'Company') (NYSE: RDDT ) securities between October 29, 2024 and May 20, 2025, inclusive (the 'Class Period'). Reddit investors have until August 18, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR REDDIT, INC. INVESTMENTS, CLICKHERETO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [email protected], by telephone at (310) 914-5007, or visit our website at What Happened? On May 1, 2025, after market hours, Reddit released its first quarter 2025 financial results, marking a third consecutive quarter with slowdown in daily active user growth. On this news, Reddit's stock price fell $4.96, or 4.2%, to close at $113.83 per share on May 2, 2025, thereby injuring investors. Then, on May 19, 2025, Wells Fargo analysts downgraded Reddit's stock, stating that Google's AI features would likely cause 'permanent' disruptions to user traffic for Reddit, and that traffic to Reddit from Google Search would continue to decline and ultimately hurt Reddit's advertising revenue. On this news, Reddit's stock price fell $5.24, or 4.6%, to close at $107.99 per share on May 19, 2025. Then, on May 21, 2025, Baird analysts downgraded Reddit's stock, citing similar concerns as Wells Fargo. On this news, Reddit's stock price fell $9.79, or 9.3%, to close at $95.85 per share on May 21, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) changes in Google Search's algorithm and features like AI Overview were causing users to stop their query on Google Search; (2) these algorithm changes were materially different than prior instances of reduced traffic to the Reddit website; (3) Defendants were aware that the increase in the query term 'Reddit' on search engines was because users were getting the sought after answer from Google Search without having to go to Reddit, and not because they intended to visit Reddit; (4) this zero-click search reality was dramatically reducing traffic to Reddit in a manner the Company was unable to overcome in the short term; (5) Defendants, therefore, lacked a reasonable basis for their outlook on user rates and advertising revenues; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Reddit securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email: [email protected] Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on CONTACT: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email:[email protected] Visit our website at: KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Law Offices of Frank R. Cruz Copyright Business Wire 2025. PUB: 06/30/2025 08:52 AM/DISC: 06/30/2025 08:52 AM
